P-glycoprotein inhibition: the past, the present and the future

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Cancer Biology

Background:

• Multidrug resistance (MDR) in cancer is often mediated by ATP binding cassette (ABC) transporters, such as P-glycoprotein (P-gp).
• P-gp actively effluxes chemotherapeutic drugs from cancer cells, reducing intracellular drug concentration and treatment efficacy.
• Modulation of P-gp and cytochrome P450 (CYP450) enzymes by co-administered compounds can lead to adverse drug-drug interactions and altered pharmacokinetics.

Purpose of the Study:

• To review existing P-glycoprotein (P-gp) inhibitors used in cancer therapy.
• To critically evaluate the design strategies and limitations of current P-gp inhibitors.
• To propose a medicinal chemist's perspective on the ideal P-gp inhibitor and future design approaches.

Main Methods:

• Literature review of P-gp inhibitors and their clinical applications.
• Analysis of P-gp inhibitor design principles and associated challenges.
• Discussion of potential future strategies for developing more effective P-gp inhibitors.

Main Results:

• Current P-gp inhibitors face challenges related to efficacy, specificity, and drug interactions.
• The co-administration of P-gp inhibitors can significantly impact anti-cancer drug metabolism and pharmacokinetic profiles.
• Existing inhibitor designs often fail to achieve the desired therapeutic outcomes due to various limitations.

Conclusions:

• There is a need for improved P-gp inhibitor design to effectively combat cancer multidrug resistance.
• Future strategies should focus on developing molecules with enhanced potency, selectivity, and favorable pharmacokinetic properties.
• Achieving an 'ideal' P-gp inhibitor requires a comprehensive medicinal chemistry approach addressing current design shortcomings.